Small is big: Pharma’s R&D brain drain continues as GSK’s Chris Carpenter jumps to upstart Rubius
The steady migration of top R&D execs out of Big Pharma and into little biotech is continuing this morning.
After spending the last decade in Big Pharma R&D, Chris Carpenter is making the leap to biotech, joining the rising star Rubius as chief medical officer.
Carpenter — a former associate professor at Harvard Med, where he ran a lab for years — spent the last six years at GSK, where he wrapped up his stint as a senior VP and head of cancer epigenetics. He jumped from Harvard to Merck to GSK, where he was credited with leading the development of Votrient. And at Merck he worked on MK-4827, which went on to become Tesaro’s PARP drug Zejula.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.